Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > Rock Creek Pharmaceuticals Inc. (RCPI)

Wow...that's got to be the best post I've

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
abew4me Member Profile
 
Followed By 7
Posts 1,123
Boards Moderated 0
Alias Born 04/30/05
160x600 placeholder
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 12/15/2014 5:05:27 PM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 12/15/2014 5:02:25 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/11/2014 5:00:50 PM
Rock Creek Pharmaceuticals Announces Listing Extension on NASDAQ "PR Newswire (US)" - 12/11/2014 4:32:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/25/2014 4:31:30 PM
Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 "PR Newswire (US)" - 11/21/2014 8:30:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/10/2014 5:03:28 PM
Rock Creek Pharmaceuticals Reports Third Quarter 2014 Results and Provides Business Update "PR Newswire (US)" - 11/10/2014 5:00:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/3/2014 5:01:19 PM
Rock Creek Pharmaceuticals Announces Presentation of Four Anatabine Projects at Neuroscience 2014 "PR Newswire (US)" - 10/23/2014 9:06:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) "Edgar (US Regulatory)" - 10/3/2014 4:30:42 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/24/2014 8:31:05 AM
Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response "PR Newswire (US)" - 9/12/2014 8:30:00 AM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/27/2014 4:23:53 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/22/2014 4:07:54 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 8/22/2014 4:00:28 PM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 8/18/2014 4:31:06 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/11/2014 5:12:27 PM
Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update "PR Newswire (US)" - 8/11/2014 4:20:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/6/2014 4:38:09 PM
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors "PR Newswire (US)" - 8/6/2014 1:04:00 PM
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference "PR Newswire (US)" - 8/4/2014 2:49:00 PM
Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical... "PR Newswire (US)" - 7/31/2014 3:31:00 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar (US Regulatory)" - 7/16/2014 4:51:04 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 7/16/2014 6:00:34 AM
abew4me   Friday, 04/26/13 09:31:04 AM
Re: NukeJohn post# 10969
Post # of 21513 
Wow...that's got to be the best post I've ever read! Thanks NukeJohn.

**************************************************************************************************

NF-kB, Inflammation, and Cancer

First, investors should take a few minutes to read this article and digest it's implications...

http://naturalsupplementsresearch.org/assets/applets/Inflammation_and_cancer-_how_hot_is_the_link.pdf

excerpts...

Although inflammation has long been known as a localized protective reaction of tissue to irritation, injury, or infection, characterized by pain, redness, swelling, and sometimes loss of function, there has been a new realization about its role in a wide variety of diseases, including cancer. While acute inflammation is a part of the defense response, chronic inflammation can lead to cancer, diabetes, cardiovascular, pulmonary, and neurological diseases. Several pro-inflammatory gene products have been identified that mediate a critical role in suppression of apoptosis, proliferation, angiogenesis, invasion, and metastasis. Among these gene products are TNF and members of its superfamily, IL-1a, IL-1b, IL-6, IL-8, IL-18, chemokines, MMP-9, VEGF, COX-2, and 5-LOX. The expression of all these genes are mainly regulated by the transcription factor NF-kB, which is constitutively active in most tumors and is induced by carcinogens (such as cigarette smoke), tumor promoters, carcinogenic viral proteins (HIV-tat, HIV-nef, HIV-vpr, KHSV, EBV-LMP1, HTLV1-tax, HPV, HCV, and HBV), chemotherapeutic agents, and g-irradiation. These observations imply that antiinflammatory agents that suppress NF-kB or NF-kB-regulated products should have a potential in both the prevention and treatment of cancer. The current review describes in detail the critical link between inflammation and cancer.

---------------------

Now....stop and think about what this article just said.

1. Chronic inflammation can lead to cancer, heart disease, pulmonary disease, neurological disease, etc.

2. Anti-inflammatory agents that suppress NF-kB can be used to prevent and/or treat cancer.

What is commercially available that can reduce NF-kB? The answer is Anatabloc.

Watch this video....

http://www.youtube.com/watch?v=AmC3Ths-Mt8

Listen to what Dr. Dale Wilson says about Chronic Low Grade Inflammation of this video on CBS Station WNEM....

http://www.youtube.com/watch?v=StVre96Vzr8

Here are some more good links on Chronic inflammation....

http://www.scientificamerican.com/article.cfm?id=chronic-inflammation-cancer

http://www.womentowomen.com/inflammation/whatischronicinflammation.aspx

http://www.lef.org/magazine/mag2011/nov201_The-Inflammatory-Factor-Underlying-Most-Cancers_01.htm

From my personal observations (and those of dozens of my friends) Anatabloc really does counter the chronic low grade inflammation that is caused by NF-kB getting out of control.

FWIW, Chronic Inflammation appears to be involved in at least seven of the top ten causes of death in the US.

http://www.lef.org/protocols/health_concerns/chronic_inflammation_01.htm

excerpts...

Chronic Inflammation

Of the ten leading causes of mortality in the United States, chronic, low-level inflammation contributes to the pathogenesis of at least seven. These include heart disease, cancer, chronic lower respiratory disease, stroke, Alzheimer’s disease, diabetes, and nephritis (Centers for Disease Control and Prevention 2011; Bastard et al. 2006; Cao 2011, Jha et al. 2009; Ferrucci et al. 2010; Glorieux et al. 2009; Kundu et al. 2008; Murphy 2012; Singh et al. 2011).

Inflammation has classically been viewed as an acute (short term) response to tissue injury that produces characteristic symptoms and usually resolves spontaneously. More contemporary revelations show chronic inflammation to be a major factor in the development of degenerative disease and loss of youthful functions.

Chronic inflammation can be triggered by cellular stress and dysfunction, such as that caused by excessive calorie consumption, elevated blood sugar levels, and oxidative stress. It is now clear that the destructive capacity of chronic inflammation is unprecedented among physiologic processes (Karin et al. 2006).

The danger of chronic, low-level inflammation is that its silent nature belies its destructive power.

In fact, stress-induced inflammation, once triggered, can persist undetected for years, or even decades, propagating cell death throughout the body. Due to the fact that it contributes so greatly to deterioration associated with the aging process, this silent state of chronic inflammation has been coined “inflammaging”.

Chronic low-level inflammation may be threatening your health at this very moment, without you realizing it. In this protocol you will learn about low-cost blood tests that can assess the inflammatory state within your body. You’ll also discover novel approaches that combat chronic inflammation to help avoid age-related health decline.

----------------------------------

What if a company discovered something that stopped the transcription of NF-kB and ended that vicious cycle of chronic low grade inflammation in the body? If it really stopped the transcription of NF-kB, and therefore stopped that low level chronic inflammation process....but it did not interfere with the normal inflammation process your body needs to fight off diseases and infections, how much would that be worth? Put another way, if something was available that significantly reduced the mortality rate associated with heart disease, cancer, chronic lower respiratory disease, stroke, Alzheimer’s disease, diabetes, etc......how much would that be worth?

Well, IMHO, it is worth Billions (with a B) and it is already available off the shelf in most cities in the US. It is called Anatabloc and it is from Rock Creek Pharmaceuticals, a division of Star Scientific (STSI).

How do I know that Anatabloc stops that chronic low grade inflammation, yet does not interfere with the body's normal immune response processes? It's simple. I have been taking Anatabloc for over a year. Since I have RA (and bronchial asthma), I have had frequent blood tests that include CRP levels due to my RA prescription drugs. My use of Anatabloc has helped me to stop taking most of my prescription medications (including Methrotrexate. Albuturol inhalers, and Singulair). Over the past few years, I had my blood tested frequently. After starting on Anatabloc (and while still on my Rx drugs), my CRP levels consistently were <.5, except for one time about 5 months ago when it was over 3. I had a blood test on a Friday and my CRP level was 3.2. Coincidentally, I wasn't feeling very good when I went in to have my blood drawn, and that night I came down with the flu and was bedridden the whole weekend. I had the full suite of symptoms (nausea, vomiting, fever, chills, body aches and pains)....but they were completely gone in about 2 days. The point I am making is that my CRP levels did in fact rise during the early stages of my illness...so the fact I took Anatabloc (which I continued throughout the duration), did not keep my body from elevating my CRP and fighting the infection. In fact, I think Anatabloc somehow shortened the duration of my flu when compared to most people.

Star Scientific has discovered something that I think will change healthcare in the US and around the world. One day soon, every major pharmaceutical company will be beating a path to their door. I'm surprised we haven't seen some type of hostile takeover attempt thus far.

IMHO, investor's should not be focusing on political contributions or frivolous lawsuits. Any significant amount of money from a teaming or partnership with a Pharma company will fix their balance sheet. Investor's focus should be on Star's discovery of Anatabine Citrate. As investors, we should be investigating the various problems caused by NF-kB in the human body, and how Anatabloc alleviates those problems.

For testimonials from Anatabloc users, check here for GNC and here for Amazon.

JMHO,

NJ

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist